The Europe non-alcoholic steatopatitis market is expected to reach US$ 6,765.21 million by 2028 from US$ 496.83 million in 2021. The market is estimated to grow at a CAGR of 45.2% from 2021 to 2028.

Non-Alcoholic Steatopatitis is an under-recognized condition. Increasing awareness of this disease among the general public and primary care physicians (PCPs) is essential for a structured referral pathway and early detection. By establishing a clear patient pathway for referrals and patient awareness campaigns, more individuals can be identified and sent to specialists for further evaluation, thereby expanding the patient pool. To raise awareness of NASH, the NASH Education Program launched the public education campaign on June 12, 2018, on “International NASH Day” to raise awareness of the non-alcoholic fatty liver disease and its more advanced form NASH, which affects over ~115 million people. NASH 24X7, a digital platform aimed at raising exposure and awareness regarding the epidemic NASH, took a few steps on June 12, 2019, on International NASH Day, including HCP support, patient awareness, and press/TV release programs. In terms of patient education, NASH Crusaders of NASH 24X7 collaborated with HCPs across India to hold many small and large-scale awareness and education workshops on liver health and the necessity of a healthy lifestyle in preventing NAFLD/NASH. On International NASH Day, several efforts were made to reach the general public, such as press releases and television programs using digital and print media. The Europe non-alcoholic steatopatitis market is expected to grow at a good CAGR during the forecast period.

Europe Non-Alcoholic Steatopatitis Revenue and Forecast to 2028 (US$ Million)

Europe Non-Alcoholic Steatopatitis Market Segmentation

The Europe Non-Alcoholic Steatopatitis market segmented into product, application, sales channel, and country. Based on product type the Europe Non-Alcoholic Steatopatitis market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period .Based on application the Europe Non-Alcoholic Steatopatitis market segmented into treatment and diagnosis. The treatment segment is dominated Europe Non-Alcoholic Steatopatitis market in 2020. Based on sales channel the Europe Non-Alcoholic Steatopatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated Europe Non-Alcoholic Steatopatitis market in 2020. Based on country, the Europe non-alcoholic steatopatitis market is segmented into Germany, the UK, France, Italy, Spain, and the rest of Europe. Germany dominated the Europe non-alcoholic steatopatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, ONE WAY LIVER SI, BioPredictive S.A.S, Siemens Healthineers AG, and Laboratory Corporation of America Holdings are among the leading companies in the Europe non-alcoholic steatopatitis market are among the leading companies in the Europe non-alcoholic steatopatitis market.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Non-Alcoholic Steatohepatitis Market – By Product
1.3.2 Europe lobal Non-Alcoholic Steatohepatitis Market – By Application
1.3.3 Europe Non-Alcoholic Steatohepatitis Market – By Sales Channel
1.3.4 Europe Non-Alcoholic Steatohepatitis Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Non-Alcoholic Steatohepatitis Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of NASH
5.1.2 Increasing Initiatives for the Awareness of NASH
5.2 Market Restraints
5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH
5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH
5.3 Market Opportunities
5.3.1 Growing Opportunities in Developing Nations
5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity
5.4 Future Trends
5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs
5.5 Impact Analysis
6. Non-alcoholic steatohepatitis (NASH) Market–Europe Analysis
6.1 Europe Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis
7. Europe Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product
7.1 Overview
7.2 Product Market Revenue and Forecast Analysis (US$ Mn)
7.3 Vitamin E and Pioglitazone
7.3.1 Overview
7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)
7.4 Ocaliva
7.4.1 Overview
7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)
7.5 Elafibranor
7.5.1 Overview
7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)
7.6 Selonsertib & Cenicriviroc
7.6.1 Overview
7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)
8. Europe Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application
8.1 Overview
8.2 Application Market Revenue and Forecast Analysis (US$ Mn)
8.3 Treatment
8.3.1 Overview
8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diagnosis
8.4.1 Overview
8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)
9. Europe Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel
9.1 Overview
9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.5 Online Provider
9.5.1 Overview
9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)
10. Europe Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis
10.1 Europe: Non-alcoholic steatohepatitis (NASH) Market
10.1.1 Overview
10.1.3 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)
10.1.3.1 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.1.1 Overview
10.1.3.1.2 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.1.3 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.1.3.1.4 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.1.3.1.5 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.1.3.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.2.1 Overview
10.1.3.2.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.2.3 France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.1.3.2.4 France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.1.3.2.5 France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.1.3.3 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.3.1 Overview
10.1.3.3.2 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.3.3 UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.1.3.3.4 UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.1.3.3.5 UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.1.3.4 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.4.1 Overview
10.1.3.4.2 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.4.3 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.1.3.4.4 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.1.3.4.5 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.1.3.5 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.5.1 Overview
10.1.3.5.2 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.5.3 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.1.3.5.4 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.1.3.5.5 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.1.3.6 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.6.1 Overview
10.1.3.6.2 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.6.3 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.1.3.6.4 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.1.3.6.5 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Cadila Pharmaceuticals Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Intercept Pharmaceuticals, Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Novartis AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Galmed Pharmaceuticals.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GENFIT.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 ONE WAY LIVER, S.L
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 BioPredictive S.A.S
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Siemens Healthineers AG
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Laboratory Corporation of America Holdings
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms

LIST OF TABLES

Table 1. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 2. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 4. France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 5. France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 6. France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 7. UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 8. UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 9. UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 10.   Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 11.   Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 12.   Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 13.   Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 14.   Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 15.   Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 16.   Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 17.   Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 18.   Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 19.   Organic Developments Done By Companies
Table 20.   Inorganic Developments Done By Companies
Table 21.   Glossary of Terms
 
 

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Non-Alcoholic Steatohepatitis market forecast.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in Europe Non-Alcoholic Steatohepatitis market forecast, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the non-alcoholic steatohepatitis, as well as those hindering it.
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

The List of Companies – Europe Non-Alcoholic Steatopatitis Market

● Cadila Pharmaceutical.
● Intercept Pharmaceutical.
● Novartis AG.
● Galmed Pharmaceutical.
● GENFIT.
● ONE WAY LIVER SI.
● BioPredictive S.A.S.
● Siemens Healthineers AG.
● Laboratory Corporation of America Holdings.